News

May 31, 2023

Alpha Cancer Technologies Presents New Data from ACT-903, an AFP-Maytansine Conjugate, in Online Publication at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Press Release

Statistically significant dose-dependent reduction in tumor volume across all treatment groups compared to control in an ovarian xenograft model. Complete elimination of tumor and 100% survival observed in the group receiving optimal treatment regimen.

Toronto, Canada, April 6, 2023 — Alpha Cancer Technologies Inc. (ACT), a biopharmaceutical company focused on developing and commercializing targeted immuno-oncology and immunomodulation therapies based on its proprietary recombinant human Alpha Fetoprotein (AFP) platform, today announced details from the company’s abstract published as part of the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO meeting will take place in Chicago from June 2-6, 2023.

View Full Press Release

April 17, 2023

Alpha Cancer Technologies (ACT) to Participate in the Gilmartin Group Private Company Showcase
Press Release
Toronto, Canada, April 12, 2023 — a biopharmaceutical company focused on developing and commercializing targeted immuno-oncology and immunomodulation therapies based on its proprietary recombinant human Alpha Fetoprotein (AFP) platform, today announced that Richard Potts, Chairman, and Dr. Igor Sherman, President & CEO, will give a corporate presentation at Gilmartin Group’s inaugural virtual Spring Private Company Showcase. The company will present on Tuesday, April 18, 2023, at 3:00 p.m. ET.

To attend the virtual presentation, please register using this link

April 6, 2023

Alpha Cancer Technologies (ACT) Publishes Pre-Clinical Study Results in Cancer Cell International Demonstrating Excellent Safety and Significant Anti-Tumor Activity from the Company’s Next Generation ADC, ACT-903
Press Release

ACT-903 conjugate demonstrated significant anti-tumor activity, with tumors becoming undetectable in 9 of 10 mice, and all 10 mice surviving through Day 60 with no obvious signs of toxicity

ACT’s technology highlights the potential to use the natural function of AFP as a carrier protein to deliver a payload uniquely targeted to cancer cells, while reducing risk of immune reactions or anti-drug antibody accumulation

Alpha fetoprotein conjugates had a very low percentage of free toxin detectable in blood after administration, and did not show any bone marrow accumulation of cytotoxic payload, suggesting limited off-target toxicity

Toronto, Canada, April 6, 2023 — a biopharmaceutical company focused on developing and commercializing targeted immuno-oncology and immunomodulation therapies based on its proprietary recombinant human Alpha Fetoprotein (AFP) platform, today announced the publication of pre-clinical study results in Cancer Cell International highlighting the company’s recombinant human AFP (ACT-101) conjugate with maytansine in mouse xenograft models of colorectal cancer. Results from the study demonstrate the exceptional safety profile and potent anti-tumor activity of multiple ACT-101 conjugates through the successful targeting of the alpha fetoprotein receptor uniquely located on cancerous cells and myeloid-derived suppressor cells (MDSCs).

View Full Press Release

April 5, 2023

Alpha Cancer Technologies Inc. Announces Acceptance of Abstract for Online Publication at the 2023 American Society of Clinical Oncology Annual Meeting
Press Release
Abstracts will be released to the public on ASCO’s Meeting Library at 5:00 p.m. ET on May 25, 2023

Toronto, Canada, April 5, 2023 —   Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on developing and commercializing targeted immuno-oncology and immunomodulation therapies based on its proprietary recombinant human Alpha Fetoprotein (AFP) platform, today announced that an abstract the company submitted has been accepted by American Society of Clinical Oncology (ASCO) for online publication at the 2023 ASCO Annual Meeting taking place from June 2-6, 2023 in Chicago.

This year, ASCO received and reviewed more than 6,500 abstracts for the 2023 ASCO Annual Meeting. Abstract titles will be posted on April 26, 2023 and abstract text will be released to the public on ASCO’s Meeting Library at 5:00 p.m. ET on May 25, 2023. For more information about the Annual Meeting, please visit: https://conferences.asco.org/am/attend.

May 26, 2022

Alpha Cancer Technologies Inc. Presents New Data from ACT-903, an AFP-maytansine Conjugate, in Online Publication at the 2022 American Society of Clinical Oncology Annual Meeting
Press Release
In a COLO-205 xenograft model, ACT-903 demonstrates tumor suppression, increased survival after single and multiple doses, and no signs of toxicity

Toronto, Canada, May 26, 2022 —  Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on developing and commercializing targeted immuno-oncology and immunology therapies based on its proprietary recombinant human Alpha Fetoprotein (AFP) platform, announced details from the company’s abstract published today at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO meeting will be held in Chicago from June 3-8, 2022.

View Full Press Release

April 15, 2022

Alpha Cancer Technologies Inc. Announces Acceptance of Abstract for Online Publication at the 2022 American Society of Clinical Oncology Annual Meeting
Press Release
Abstracts will be released to the public on ASCO’s Meeting Library at 5:00 p.m. ET on May 26, 2022

Toronto, Canada, April 14, 2022 —   Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on developing and commercializing targeted immuno-oncology and immunology therapies based on its proprietary recombinant human Alpha Fetoprotein (AFP) platform, today announced that an abstract the company submitted has been accepted by American Society of Clinical Oncology (ASCO) for the 2022 ASCO Annual Meeting and will be published in an online supplement of the Journal of Clinical Oncology following the meeting. ASCO will be held in Chicago from June 3-8, 2022.

This year, ASCO received and reviewed more than 6,000 abstracts for the 2022 ASCO Annual Meeting. For more information about the Annual Meeting, please visit: https://conferences.asco.org/am/attend. Per ASCO’s Embargo & Release Information, abstracts will be released to the public on ASCO’s Meeting Library at 5:00 p.m. ET on May 26, 2022.

September 16, 2021

Alpha Cancer Technologies Inc. Presents New Data from ACT-903, an AFP-maytansine Conjugate, at 2021 European Society of Medical Oncology Annual Meeting
Press Release

Preclinical studies show ACT-903 demonstrates tumor suppression, increased survival, maytansine and metabolite accumulation in the tumor, and no signs of toxicity

Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on developing and commercializing targeted immuno-oncology and immunology therapies based on its proprietary recombinant human Alpha Fetoprotein (AFP) platform, today announced the presentation of new preclinical data from the Company’s investigational therapy, ACT-903 at the European Society of Medical Oncology (ESMO) Annual Meeting being held virtually September 16-21, 2021.

View Full Press Release
View Poster

August 17, 2021

AFP-Maytansine Conjugate – a Novel Targeted Cancer Immunotherapy
Press Release

Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on developing and commercializing targeted immuno-oncology and immunology therapies based on its proprietary recombinant human Alpha Fetoprotein platform, today announced that its abstract featuring data from the Company’s investigational therapy, ACT-903, has been selected for presentation at the European Society of Medical Oncology (ESMO) Annual Meeting being held virtually September 16-21, 2021.

Details about the abstract selected for poster publication can be found below:

Title: AFP-Maytansine Conjugate – a Novel Targeted Cancer Immunotherapy
Abstract Number: 523P
Authors: I. Sherman, R. Boohaker, K. Stinson, P. Griffin, W. Hill
Abstracts are under embargo until 5:00 p.m. ET on Sept. 15, 2021.

For more information about the Annual Meeting, please visit: https://www.esmo.org/meetings/esmo-congress-2021

July 21, 2020

Alpha Cancer Technologies to License AbSci’s SoluPro Strain for the Expression of Alpha-Fetoprotein
Press Release

AbSci, a growth-stage synthetic biology company whose Protein Printing™ technology enables rapid and low-cost biomanufacturing of difficult-to-produce biotherapeutics, today announced that it has entered into an agreement to license its E. coli SoluPro® protein expression technology to Alpha Cancer Technologies for the production of Recombinant Human Alpha-fetoprotein (hAFP). hAFP is a natural human protein produced by human embryo and yolk sac during development and can be used in the treatment of various autoimmune diseases and cancers. This license is an expansion of a previous collaboration between the parties that began last year.

Download